Opexa Therapeutics Inc. (NASDAQ:OPXA)’s share price traded up 3.2% during mid-day trading on Wednesday . The company traded as high as $4.22 and last traded at $4.14, with a volume of 57,262 shares trading hands. The stock had previously closed at $4.01.

A number of equities analysts have issued reports on the company. Chardan Capital reiterated a “buy” rating and set a $6.00 price target on shares of Opexa Therapeutics in a research note on Sunday. Maxim Group restated a “buy” rating on shares of Opexa Therapeutics in a research note on Friday, June 10th. Finally, Aegis restated a “buy” rating and issued a $9.00 target price on shares of Opexa Therapeutics in a research note on Wednesday, March 16th.

The stock’s market cap is $29.25 million. The firm has a 50-day moving average of $3.39 and a 200-day moving average of $2.55.

Opexa Therapeutics (NASDAQ:OPXA) last posted its quarterly earnings results on Thursday, May 12th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.35) by $0.04. During the same quarter in the previous year, the company earned ($0.96) earnings per share. Equities analysts expect that Opexa Therapeutics Inc. will post ($0.99) EPS for the current year.

Opexa Therapeutics, Inc (Opexa) is a biopharmaceutical company developing a personalized immunotherapy with the potential to treat various illnesses, including multiple sclerosis (MS), as well as other autoimmune diseases, such as neuromyelitis optica (NMO). These therapies are based on the Company’s T-cell technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.